ABL1 monoclonal antibody, clone 7B11D6 供应商 Abnova 产品货号 MAB17689 产品报价 ¥询价/100uL 产品说明书 点击查看 购买方式 在线支付宝及网银支付、支票、现金、电汇,或拨打全国免费服务电话4006800868与我们联系。 产品新闻 背景资料 待更新 应用类型 ...
1:50-1:100 - 免疫沉淀 (IP) 5 µg - 产品规格 种属反应 Human, Mouse 已发表种属 Human 宿主/亚型 Mouse / IgG2a 分类 Monoclonal 类型 Antibody 克隆号 7C6 抗原 Bcr686 thyroglobulin conjugate corresponding to human BCR sequence 686-696 (SSINEEITPRRQS) 查看免疫原 偶联物...
MAb anti-Staphylococcal enterotoxins ( MAb -SE) were produced in mice with a mixture of reference SE types A, B, C 1 and D at a concentration of 1 μg each per mouse; the last booster injection was by intrasplenic route. Nine clones were chosen, two produced anti-SEB and anti-SED,...
EPT-A-6143-100 Epigentek RNF168 Monoclonal Antibody [3E1] (100 µg) EPT-A-6144-100 Epigentek TIPIN Monoclonal Antibody [1G11] (100 µg) EPT-A-6145-100 Epigentek FRAP1 Monoclonal Antibody [2C5] (100 µg) EPT-A-6146-100 Epigentek RPS6KA1 Monoclonal Antibody [2E3] (100 µ...
against a truncated gst-abl1 recombinant protein (1). view more 产品信息 应用 建议稀释比 已发表文章 免疫印迹(wb) 1:500-1:2,000 - 酶联免疫吸附实验(elisa) 1:10,000 - 产品规格 种属反应 human 宿主/亚型 mouse/ igg1 分类 monoclonal 类型 antibody 克隆号 7b11d6 抗原 purified recombinant ...
To amplify IgG variable genes, we first carried out the RT reaction in the 96-well PCR plate. Then heavy chain and light chain genes were separately amplified, sequenced, synthesized, and cloned into the backbone of antibody expression vectors containing the constant regions of human IgG1 (Sango...
the development of distant metastasis, which were associated with increased invasiveness and resistance to chemotherapy, while CD26− CRC cells did not, suggesting the existence of CD26+ CSCs in CRC61. In summary, we identified CD26 expression not only in activated OCs but also in MM cells ...
1:200-1:1,000 - 酶联免疫吸附实验 (ELISA) 1:10,000 - 产品规格 种属反应 Human, Mouse 宿主/亚型 Mouse / IgG1 分类 Monoclonal 类型 Antibody 克隆号 1H1 抗原 Purified recombinant fragment of ABL2 expressed in E. Coli. 偶联物 Unconjugated 形式 Liquid 浓度 Conc. Not...
A deeper knowledge of the mechanisms underlying resistance to rituximab is also necessary in order to improve the activity of this and of similar therapeutics. Finally, new antibodies and biological agents are entering the scene and their advantages over rituximab will have to be assessed. We will...
In recent years, monoclonal antibodies (mAbs), as potent antitumor tools, have gained increasing importance in the clinic. The use of antibody engineering methods has made it possible for investigators to develop antibody structures with improved antitum